13 recruiting, 9 active not recruiting, 8 completed, 6 terminated. 28 Phase 2, 19 Phase 1, 2 Early Phase 1, 1 Phase 3.
Follow defactinib: new trials by email Literature Review of defactinib trials Research Report on defactinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 23 | 2027-01-01 | 2026-08-04 |
| Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation - MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma | Early Phase 1 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 22 | 2026-11-10 | 2026-08-26 |
| Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma Avutometinib (VS-6766) + Defactinib (VS-6063) - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | University of Virginia | 31 | 2026-10-01 | 2026-09-17 |
| Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) avutometinib + defactininb combination - Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | Not yet recruiting | Verastem, Inc. | 2 | 2026-08-03 | 2026-08-05 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer Avutometinib, defactinib, Everolimus - Phase IB, Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 31 | 2026-05-13 | 2026-06-29 |
| Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma Stereotactic body radiotherapy, Defactinib, Avutometinib - Pancreatic Adenocarcinoma, Cancer of the Pancreas | Phase 2 | Recruiting | Washington University School of Medicine | 36 | 2026-04-10 | 2026-04-15 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Verastem, Inc. | 616 | 2025-06-24 | 2026-10-23 |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Defactinib, Cetuximab, Avutometinib - Advanced Colorectal Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 33 | 2025-02-24 | 2026-09-25 |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients Avutometinib (VS-6766) + Defactinib (VS-6063) - Low Grade Serous Ovarian Cancer, Ovarian Cancer | Phase 2 | Active not recruiting | Verastem, Inc. | 16 | 2024-10-30 | 2025-12-17 |
| Avutometinib and Defactinib in Diffuse Gastric Cancer Avutometinib, Defactinib - Gastric Cancer, Stomach Cancer | Phase 2 | Recruiting | Ryan H. Moy, MD, PhD | 27 | 2024-10-28 | 2025-11-04 |
| Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Avutometinib, Biopsy, Biospecimen Collection - Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma | Phase 2 | Recruiting | Emory University | 50 | 2024-07-31 | 2026-04-06 |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer Avutometinib, Defactinib, Letrozole - Low-Grade Serous Ovarian Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-04-29 | 2026-10-23 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer avutometinib, Defactinib, Pegylated liposomal doxorubicin - Low Grade Serous Ovarian Cancer | Phase 3 | Recruiting | Verastem, Inc. | 270 | 2024-03-18 | 2026-10-07 |
| A Study of Avutometinib and Defactinib in People With Thyroid Cancer Avutometinib, Defactinib - Thyroid Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-08-16 | 2026-10-15 |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma Avutometinib, Biospecimen Collection, Defactinib - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Active not recruiting | Emory University | 14 | 2023-07-28 | 2025-12-15 |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel - KRAS Activating Mutation, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Verastem, Inc. | 40 | 2023-03-22 | 2025-09-02 |
| A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer Avutometinib (VS-6766), Defactinib - Mesonephric Gynecologic Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2023-03-15 | 2026-10-08 |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib Avutometinib (VS-6766) + defactinib - Endometrioid Cancer, Mucinous Ovarian Cancer | Phase 2 | Recruiting | University of Oklahoma | 55 | 2023-02-06 | 2025-10-22 |
Showing 20 of 42. Sign in to see all of them.
Pancreatic Neoplasms (10) · Ovarian Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (4) · Mesothelioma, Malignant (4) · Glioblastoma (3) · Neoplasm Metastasis (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Melanoma (2) · Mesothelioma (2) · Neoplasms (2) · Stomach Neoplasms (2) · Thyroid Neoplasms (2) · Uterine Cervical Neoplasms (2)
Verastem, Inc. (17) · Memorial Sloan Kettering Cancer Center (3) · Washington University School of Medicine (3) · Emory University (2) · Institute of Cancer Research, United Kingdom (2) · M.D. Anderson Cancer Center (2) · Clinical Hub for Interventional Research (CHOIR) (1) · Girish Dhall, MD (1) · Lei Zheng (1) · Michael McHale (1) · NHS Greater Glasgow and Clyde (1) · National Cancer Institute (NCI) (1) · Raphael Bueno, MD (1) · Ryan H. Moy, MD, PhD (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (33) · United Kingdom (8) · France (7) · Spain (6) · Australia (4) · Belgium (4) · Canada (4) · Italy (4) · Japan (4) · Netherlands (3) · Germany (2) · New Zealand (2) · Poland (2) · Puerto Rico (2) · Denmark (1)
MD Verastem (5) · Rachel Grisham, MD (4) · Hagop Youssoufian (3) · Hagop Youssoufian, MD (2) · Alan Ho, MD, PhD (1) · Arsen Osipov, MD (1) · Carl DeSelm, M.D., Ph.D. (1) · Christian Ottensmeier (1) · Christina Washington, MD (1) · Christine Parseghian, MD (1) · Conor E Steuer (1) · David E Gerber, M.D. (1) · Dean Fennell (1) · Girish Dhall, MD (1) · Hagop Youssoufian, m (1)
PMID 37598000, PMID 40644648, PMID 26334219, PMID 26586415, PMID 27025608, PMID 30785827, PMID 32463741, PMID 33048619, PMID 34663687, PMID 35133871, PMID 35138919, PMID 35285277, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38493021, PMID 38591867, PMID 39375168, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40579546, PMID 40865033, PMID 41066729, PMID 41384753, PMID 41790275, PMID 42814800
P30CA138292 (2), 2015 (1), 2017 (1), P01CA257906 (1), R01CA248917 (1), U10CA180820 (1), U24CA196172 (1)